BeiGene Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BeiGene stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BGNE, but not buy additional shares or sell existing shares.
View analyst ratings for BeiGene or view top-rated stocks.

Wall Street analysts have given BeiGene a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BeiGene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BeiGene.

BeiGene, Ltd. (NASDAQ:BGNE) issued its quarterly earnings data on Friday, May, 7th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.90) by $2.59. BeiGene had a negative net margin of 135.24% and a negative trailing twelve-month return on equity of 31.71%.
View BeiGene's earnings history.

BeiGene's stock was trading at $145.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BGNE shares have increased by 136.7% and is now trading at $344.82.
View which stocks have been most impacted by COVID-19.

9 analysts have issued 12 month price objectives for BeiGene's stock. Their forecasts range from $190.00 to $429.00. On average, they expect BeiGene's share price to reach $334.88 in the next year. This suggests that the stock has a possible downside of 2.9%.
View analysts' price targets for BeiGene or view top-rated stocks among Wall Street analysts.

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

Some companies that are related to BeiGene include GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Genmab A/S (GMAB), Genmab A/S (GNMSF), Royalty Pharma (RPRX), Takeda Pharmaceutical (TKPYY), MERCK Kommanditgesellschaft auf Aktien (MKGAF) and Horizon Therapeutics Public (HZNP).
View all of BGNE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

BeiGene's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital International Investors (6.32%), Baillie Gifford & Co. (4.83%), Primecap Management Co. CA (4.24%), BlackRock Inc. (2.85%), Boxer Capital LLC (0.83%) and Price T Rowe Associates Inc. MD (0.80%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene.

BGNE stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Sands Capital Management LLC, Price T Rowe Associates Inc. MD, Canada Pension Plan Investment Board, Barclays PLC, Bellevue Group AG, Indus Capital Partners LLC, and UBS Group AG. Company insiders that have sold BeiGene company stock in the last year include Bros Advisors Lp Baker, Howard Liang, Jane Huang, John Oyler, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene or view top insider-selling stocks.

BGNE stock was bought by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Capital International Investors, Baillie Gifford & Co., Goldman Sachs Group Inc., New York State Common Retirement Fund, Mirae Asset Global Investments Co. Ltd., USS Investment Management Ltd, and Van ECK Associates Corp.
View insider buying and selling activity for BeiGene or or view top insider-buying stocks.

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BGNE stock can currently be purchased for approximately $344.82.

BeiGene has a market capitalization of $31.73 billion and generates $308.87 million in revenue each year. The company earns $-1,596,910,000.00 in net income (profit) each year or ($19.13) on an earnings per share basis.

BeiGene employs 5,300 workers across the globe.

BeiGene was founded in 2010.

The official website for BeiGene is www.beigene.com.

BeiGene is headquartered at 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108.

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]